Post-relapse survival was similar in adjusted ( p = 023 ) and unadjusted analyses ( p = 033 ) for the comparison of XELOX or FOLFOX versus leucovorin and fluorouracil , and was also similar for capecitabine-based regimens versus leucovorin and fluorouracil-based regimens ( unadjusted p = 026 ) .